Molomics Biotech

Better drug candidates through our novel Artificial Intelligence Technology


Jascha Blobel (See Profile)




In vitro, proof of concept



Molomics uses a next generation AI technology to discover better small molecule drugs.

Molomics focuses on new improved drugs for Parkinson Disease, a huge unmet medical need.

Current investors will participate in this seed round again with more than EURO 150k.

Molomics plans to partner with biotech or pharma companies for other indications.

Companies with similar AI focused business plans achieved rapid increases in valuation during their first five years

This information is confidential, do not share or copy.

Under evaluation at least till: 27th of November

If you want to have more information or you want to review the project, you have to login or register


©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar